Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Rosiglitazone and delayed onset of proliferative diabetic retinopathy.

Shen LQ, Child A, Weber GM, Folkman J, Aiello LP.

Arch Ophthalmol. 2008 Jun;126(6):793-9. doi: 10.1001/archopht.126.6.793.

PMID:
18541841
2.

Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema.

Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU; Diabetic Retinopathy Clinical Research Network Study Group..

Invest Ophthalmol Vis Sci. 2008 May;49(5):1745-52. doi: 10.1167/iovs.07-1257. Epub 2008 Mar 3.

3.
4.

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group..

Am J Cardiol. 2007 Jun 18;99(12A):4i-20i. Epub 2007 Apr 12. Review.

PMID:
17599424
5.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group., Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
6.

Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M; ACCORD Study Group..

Am J Cardiol. 2007 Jun 18;99(12A):103i-111i. Epub 2007 Apr 13.

PMID:
17599420
7.

The record on rosiglitazone and the risk of myocardial infarction.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jul 5;357(1):67-9. Epub 2007 Jun 5. No abstract available.

8.

Rosiglitazone and cardiotoxicity--weighing the evidence.

Nathan DM.

N Engl J Med. 2007 Jul 5;357(1):64-6. Epub 2007 Jun 5. No abstract available.

9.

Rosiglitazone--continued uncertainty about safety.

Drazen JM, Morrissey S, Curfman GD.

N Engl J Med. 2007 Jul 5;357(1):63-4. Epub 2007 Jun 5. No abstract available.

10.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group..

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

11.

Rosiglitazone: seeking a balanced perspective.

[No authors listed]

Lancet. 2007 Jun 2;369(9576):1834. No abstract available.

PMID:
17544746
12.

Rosiglitazone and cardiovascular risk.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jun 14;356(24):2522-4. Epub 2007 May 21. No abstract available.

13.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

14.

Diabetic macular edema associated with glitazone use.

Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, Williams DF.

Retina. 2006 May-Jun;26(5):562-70.

PMID:
16770264
15.

Diabetic retinopathy in a multi-ethnic cohort in the United States.

Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S.

Am J Ophthalmol. 2006 Mar;141(3):446-455.

16.

Rosiglitazone (Avandia) and macular edema.

Kendall C, Wooltorton E.

CMAJ. 2006 Feb 28;174(5):623. Epub 2006 Feb 8. No abstract available.

17.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators..

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598
18.

Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus.

Colucciello M.

Arch Ophthalmol. 2005 Sep;123(9):1273-5. No abstract available.

PMID:
16157815
19.

A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes.

Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA.

Diabetes. 2004 Nov;53(11):2883-92.

20.

Partial resolution of diabetic macular oedema after systemic treatment with furosemide.

Ciardella AP.

Br J Ophthalmol. 2004 Sep;88(9):1224-5. No abstract available.

Supplemental Content

Support Center